Metagenomi 2025 Q3 Earnings Widened Loss Amid 24.8% Revenue Decline

Metagenomi (MGX) reported Q3 2025 earnings on Nov 13, 2025, with results showing a 24.8% revenue drop to $8.66 million and a 8.6% wider net loss of $20.39 million. While the GAAP EPS of -$0.55 beat estimates by $0.25, revenue fell short by $0.78 million. The company announced a 25% workforce reduction and leadership transition as part of a strategic restructuring.

Revenue

Total revenue for Q3 2025 declined 24.8% year-over-year to $8.66 million, driven entirely by collaboration revenue, which accounted for the full $8.66 million. The absence of diversified revenue streams highlights operational concentration risks.

Earnings/Net Income

The company’s net loss widened to $20.39 million in Q3 2025, an 8.6% increase from $18.77 million in the prior-year period. Earnings per share (EPS) fell to -$0.55, a 7.8% deeper loss compared to -$0.51. The sustained losses underscore persistent financial challenges.

Post-Earnings Price Action Review

Following the earnings report, Metagenomi’s stock price dropped 7.00% in the latest trading day, 17.70% over the past week, and 34.74% month-to-date. The steep declines reflect investor concerns over the revenue shortfall, expanded losses, and strategic overhauls. Market sentiment remains bearish, with the stock underperforming broader indices.

Additional News

Metagenomi announced a 25% workforce reduction and appointed Jian Irish, Ph.D., as CEO, replacing founder Brian Thomas, who remains on the board. The restructuring aims to extend the company’s cash runway to Q4 2027 and prioritize its MGX-001 hemophilia A program, which demonstrated curative factor VIII activity in non-human primates. Preclinical data supports a planned pre-IND meeting in Q4 2025 and IND/CTA submissions by Q4 2026. The company also reduced R&D and G&A expenses, aligning with its focus on core programs.